Results from the BRIGHT Trial of First-Line Bendamustine/Rituximab versus R-CHOP/R-CVP in Advanced Indolent NHL or MCL


Results from the BRIGHT Trial of First-Line Bendamustine/Rituximab versus R-CHOP/R-CVP in Advanced Indolent NHL or MCL
Slides from presentations at ICML 2013/ASCO 2013 and transcribed comments from recent interviews with Jonathan W Friedberg, MD, MMSc (7/19/13) and Ian W Flinn, MD, PhD (10/5/13)
Flinn I et al. The BRIGHT study of first-line bendamustine-rituximab (BR) or R-CHOP/R-CVP in advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL). Proc ICML 2013;Abstract 084.

Flinn I et al. Secondary efficacy subanalysis by histology from the Phase III BRIGHT study: First-line bendamustine-rituximab (BR) compared with standard R-CHOP/R-CVP for patients with advanced indolent non-Hodgkin lymphoma (NHL) or mantle cell lymphoma (MCL). Proc ASCO 2013;Abstract 8537.

Dr Friedberg is Samuel Durand Professor of Medicine and Director of the Wilmot Cancer Center at the University of Rochester in Rochester, New York.

Dr Flinn is Director of Blood Cancer Research at Sarah Cannon Research Institute in Nashville, Tennessee.